These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 17621181

  • 1. Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration.
    Emerson GG, Flaxel CJ, Lauer AK, Stout JT, Emerson MV, Nolte S, Wilson DJ, Klein ML.
    Retina; 2007; 27(6):724-9. PubMed ID: 17621181
    [Abstract] [Full Text] [Related]

  • 2. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S, Kaplowitz K, Brubaker JW, Updike PG, Collins AT, Walsh AC, Romano PW, Sadda SR.
    Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
    [Abstract] [Full Text] [Related]

  • 3. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
    Quiram PA, Hassan TS, Williams GA.
    Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ.
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [Abstract] [Full Text] [Related]

  • 5. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Mar; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Mar; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 7. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T.
    Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
    [Abstract] [Full Text] [Related]

  • 8. RPE tears after pegaptanib treatment in age-related macular degeneration.
    Chang LK, Flaxel CJ, Lauer AK, Sarraf D.
    Retina; 2007 Sep; 27(7):857-63. PubMed ID: 17891009
    [Abstract] [Full Text] [Related]

  • 9. Compassionate use of intravitreal pegaptanib in patients with age-related macular degeneration.
    Ricci F, Missiroli F, Cedrone C, Grossi M, Regine F.
    Semin Ophthalmol; 2010 Sep; 25(1-2):16-20. PubMed ID: 20507192
    [Abstract] [Full Text] [Related]

  • 10. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, Schmidt-Erfurth U.
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C.
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [Abstract] [Full Text] [Related]

  • 12. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupDepartment of Ophthalmology, Harvard Medical School, Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. djdamico@meei.harvard.edu, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B.
    Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN.
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [Abstract] [Full Text] [Related]

  • 14. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML.
    Retina; 2007 Jul; 27(4):439-44. PubMed ID: 17420695
    [Abstract] [Full Text] [Related]

  • 15. Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series.
    Atmani K, Coscas F, Coscas G, Soubrane G.
    Eye (Lond); 2009 May; 23(5):1150-4. PubMed ID: 18636083
    [Abstract] [Full Text] [Related]

  • 16. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [Abstract] [Full Text] [Related]

  • 17. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV, Steén B, Seregard S, Kvanta A.
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [Abstract] [Full Text] [Related]

  • 18. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupCentre for Vision Sciences, The Queen's University of Belfast and The Royal Victoria Hospital, Belfast, United Kingdom., Chakravarthy U, Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Patel M.
    Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500
    [Abstract] [Full Text] [Related]

  • 19. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
    Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M.
    Retina; 2010 Sep; 30(7):1034-8. PubMed ID: 20616682
    [Abstract] [Full Text] [Related]

  • 20. Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events.
    Battaglia Parodi M, Di Bartolo E, Brue C, Cappello E, Furino C, Giuffrida S, Imparato M, Reibaldi M.
    Eur J Ophthalmol; 2018 Jan; 28(1):58-62. PubMed ID: 29077191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.